Inactief instrument

Andere talen Santhera Pharmaceuticals Holding AG Xetra

Aandelen

S3F

CH0027148649

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Santhera Publishes Agenda for its Annual General Meeting	28/05
Santhera Publishes Annual Report 2023	28/05
Santhera dans les chiffres noirs en 2023	25/04
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	25/04
Santhera dank Catalyst-Deal mit gutem Finanzpuffer - ab 2026 Break-Even geplant	25/04
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	25/04
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	17/04
Spexis: sursis concordataire prolongé de 4 mois après réception d'un paiement	17/04
Santhera obtient un statut d'examen prioritaire en Chine pour le vamorolone	27/03
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	27/03
Santhera kommt mit möglicher Zulassung von Vamorolon in China entscheidend voran	27/03
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	27/03
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	27/03
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	14/03
Santhera: lancement de l'Agamree contre la myopathie de Duchenne aux USA	14/03
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	14/03
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	21/02
Aktien Schweiz auf Erholungskurs	14/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Santhera Pharmaceuticals Holding AG Xetra

Aandelen

S3F

CH0027148649

Andere talen

Filters